The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

PLoS Pathogens

Volumn 9, Issue 1, 2013, Pages

  Tavis, John E ^a,b   Cheng, Xiaohong ^a   Hu, Yuan ^a,c   Totten, Michael ^a   Cao, Feng ^a,b   Michailidis, Eleftherios ^d   Aurora, Rajeev ^a   Meyers, Marvin J ^a   Jacobsen, E Jon ^a   Parniak, Michael A ^d   Sarafianos, Stefan G ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS RIBONUCLEASE H; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE ENZYME; UNCLASSIFIED DRUG; VIRUS ENZYME;

AFFINITY CHROMATOGRAPHY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; ELECTROPHORESIS; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE MUTATION; GENOTYPE; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; SOUTHERN BLOTTING; VIRUS CAPSID; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOTYPE; HEPATITIS B VIRUS; HIV INTEGRASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; RECOMBINANT PROTEINS; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84875066869     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003125     Document Type: Article

References (106)

1. Seeger C, Zoulim F, Mason WS (2007) Hepadnaviruses. In: Knipe DM, Howley P, Griffin DE, Lamb RA, Martin MA et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. pp. 2977-3029.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP, (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28: 112-125.
3. Ganem D, Prince AM, (2004) Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129.
4. Lavanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107.
5. Tavis JE, Badtke MP (2009) Hepadnaviral Genomic Replication. In: Cameron CE, Götte M, Raney KD, editors. Viral Genome Replication. New York: Springer Science+Business Media, LLC. pp. 129-143.
6. Cox N, Tillmann H, (2011) Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 16: 713-729.
7. Kwon H, Lok AS, (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8: 275-284.
8. Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, et al. (2012) Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol 44: 1060-1071.
9. Zoulim F, (2006) Antiviral therapy of chronic hepatitis B. Antiviral Res 71: 206-215.
10. van Bommel F, De Man RA, Wedemeyer H, Deterding K, Petersen J, et al. (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80.
11. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, et al. (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139: 1218-1229.
12. Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, et al. (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455.
13. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, et al. (2010) Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52: 1611-1620.
14. Perrillo RP, Marcellin P, (2010) Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. Antivir Ther 15: 13-22.
15. Zoulim F, Locarnini S, (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608.
16. Lau GK, (2009) A new magic bullet for chronic hepatitis B infection: Is this the end of the story? Gastroenterology 136: 1830-1832.
17. Buti M, Brosa M, Casado MA, Rueda M, Esteban R, (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51: 640-646.
18. Ruggeri M, Cicchetti A, Gasbarrini A, (2011) The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy 102: 72-80.
19. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, et al. (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51: 581-592.
20. Tuttleman JS, Pourcel C, Summers J, (1986) Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47: 451-460.
21. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, et al. (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750-1758.
22. Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, et al. (2011) Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J Med Virol 83: 602-607.
23. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL, (2006) One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 11: 909-916.
24. Coffin CS, Mulrooney-Cousins PM, Peters MG, van MG, Roberts JP, et al. (2011) Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat 18: 415-423.
25. Zoulim F, (2004) Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 15: 299-305.
26. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, et al. (2010) Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 105: 989-1004.
27. Ghany M, Liang TJ, (2007) Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132: 1574-1585.
28. Hostomsky Z, Hostomska Z, Matthews DA (1993) Ribonuclease H. In: Linn SM, Lloyd RS, Roberts RJ, editors. Nulceases. Plainview, NY: Cold Spring Harbor Laboratory Press. pp. 341-376.
29. Yang W, Steitz TA, (1995) Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3: 131-134.
30. Katayanagi K, Miyagawa M, Matsushima M, Ishikawa M, Kanaya S, et al. (1990) Three-dimensional structure of ribonuclease H from E. coli. Nature 347: 306-309.
31. Rice PA, Baker TA, (2001) Comparative architecture of transposase and integrase complexes. Nat Struct Biol 8: 302-307.
32. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, et al. (1994) Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266: 1981-1986.
33. Ariyoshi M, Vassylyev DG, Iwasaki H, Nakamura H, Shinagawa H, et al. (1994) Atomic structure of the RuvC resolvase: a holliday junction-specific endonuclease from E. coli. Cell 78: 1063-1072.
34. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L, (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305: 1434-1437.
35. Frank P, Braunshofer-Reiter C, Wintersberger U, Grimm R, Busen W, (1998) Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII. Proc Natl Acad Sci USA 95: 12872-12877.
36. Frank P, Braunshofer-Reiter C, Poltl A, Holzmann K, (1998) Cloning, subcellular localization and functional expression of human RNase HII. Biol Chem 379: 1407-1412.
37. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W, (2005) Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121: 1005-1016.
38. Klumpp K, Hang JQ, Rajendran S, Yang Y, Derosier A, et al. (2003) Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 31: 6852-6859.
39. Nowotny M, Yang W, (2006) Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J 25: 1924-1933.
40. Keck JL, Goedken ER, Marqusee S, (1998) Activation/attenuation model for RNase H. A one-metal mechanism with second-metal inhibition. J Biol Chem 273: 34128-34133.
41. Goedken ER, Marqusee S, (2001) Co-crystal of Escherichia coli RNase HI with Mn2+ ions reveals two divalent metals bound in the active site. J Biol Chem 276: 7266-7271.
42. Li MD, Bronson DL, Lemke TD, Faras AJ, (1995) Phylogenetic analyses of 55 retroelements on the basis of the nucleotide and product amino acid sequences of the pol gene. Mol Biol Evol 12: 657-670.
43. McClure MA (1993) Evolutionary History of Reverse Transcriptase. In: Skalka AM, editor. Reverse Transcriptase. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp. 425-444.
44. Poch O, Sauvaget I, Delarue M, Tordo N, (1989) Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8: 3867-3874.
45. Hu J, Seeger C, (1996) Hsp90 is required for the activity of a hepatitis b virus reverse transcriptase. Proc Natl Acad Sci USA 93: 1060-1064.
46. Gong Y, Yao E, Tavis JE, (2001) Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates. BMC Microbiology 1: 12.
47. Radziwill G, Zentgraf H, Schaller H, Bosch V, (1988) The duck hepatitis B virus DNA polymerase is tightly associated with the viral core structure and unable to switch to an exogenous template. Virology 163: 123-132.
48. Gerelsaikhan T, Tavis JE, Bruss V, (1996) Hepatitis B Virus Nucleocapsid Envelopment Does Not Occur without Genomic DNA Synthesis. J Virol 70: 4269-4274.
49. Wei Y, Tavis JE, Ganem D, (1996) Relationship between Viral DNA Synthesis and Virion Envelopment in Hepatitis B Viruses. J Virol 70: 6455-6458.
50. Chen Y, Robinson WS, Marion PL, (1994) Selected Mutations of the Duck Hepatitis B Virus P Gene RNase H Domain Affect both RNA Packaging and Priming of Minus-Strand DNA Synthesis. J Virol 68: 5232-5238.
51. Chang C, Zhou S, Ganem D, Standring DN, (1994) Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be cis Preferential. J Virol 68: 5225-5231.
52. Radziwill G, Tucker W, Schaller H, (1990) Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 64: 613-620.
53. Chang LJ, Hirsch RC, Ganem D, Varmus HE, (1990) Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol 64: 5553-5558.
54. Wei X, Peterson DL, (1996) Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase. J Biol Chem 271: 32617-32622.
55. Lee YI, Hong YB, Kim Y, Rho HM, Jung G, (1997) RNase H activity of human hepatitis B virus polymerase expressed in Escherichia coli. Biochem Biophys Res Commun 233: 401-407.
56. Choi J, Kim EE, Park YI, Han YS, (2002) Expression of the active human and duck hepatitis B virus polymerases in heterologous system of Pichia methanolica. Antiviral Res 55: 279-290.
57. Potenza N, Salvatore V, Raimondo D, Falanga D, Nobile V, et al. (2007) Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active. Protein Expr Purif 55: 93-99.
58. Freed EO, Martin MA (2007) HIVs and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. pp. 2107-2185.
59. Klarmann GJ, Hawkins ME, Le Grice SF, (2002) Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target. AIDS Rev 4: 183-194.
60. Klumpp K, Mirzadegan T, (2006) Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 12: 1909-1922.
61. Takada K, Bermingham A, O'Keefe BR, Wamiru A, Beutler JA, et al. (2007) An HIV RNase H inhibitory 1,3,4,5-tetragalloylapiitol from the African plant Hylodendron gabunensis. J Nat Prod 70: 1647-1649.
62. Bokesch HR, Wamiru A, Le Grice SF, Beutler JA, McKee TC, et al. (2008) HIV-1 ribonuclease H inhibitory phenolic glycosides from Eugenia hyemalis. J Nat Prod 71: 1634-1636.
63. Wendeler M, Lee HF, Bermingham A, Miller JT, Chertov O, et al. (2008) Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem Biol 3: 635-644.
64. Fuji H, Urano E, Futahashi Y, Hamatake M, Tatsumi J, et al. (2009) Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. J Med Chem 52: 1380-1387.
65. Su HP, Yan Y, Prasad GS, Smith RF, Daniels CL, et al. (2010) Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 84: 7625-7633.
66. Di GM, Olson M, Prashad AS, Bebernitz G, Luckay A, et al. (2010) Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg Med Chem Lett 20: 398-402.
67. Chung S, Wendeler M, Rausch JW, Beilhartz G, Gotte M, et al. (2010) Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob Agents Chemother 54: 3913-3921.
68. Williams PD, Staas DD, Venkatraman S, Loughran HM, Ruzek RD, et al. (2010) Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett 20: 6754-6757.
69. Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, et al. (2011) Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J Med Chem 54: 4462-4473.
70. Billamboz M, Bailly F, Lion C, Touati N, Vezin H, et al. (2011) Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function. J Med Chem 54: 1812-1824.
71. Didierjean J, Isel C, Querre F, Mouscadet JF, Aubertin AM, et al. (2005) Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob Agents Chemother 49: 4884-4894.
72. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, et al. (2005) Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 33: 1249-1256.
73. Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, et al. (2009) Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 17: 1625-1635.
74. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, et al. (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 278: 2777-2780.
75. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, Coy-Simandle K, et al. (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol 1: 702-712.
76. Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, et al. (2009) RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem 52: 5781-5784.
77. Suchaud V, Bailly F, Lion C, Tramontano E, Esposito F, et al. (2012) Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorg Med Chem Lett 22: 3988-3992.
78. Gong Q, Menon L, Ilina T, Miller LG, Ahn J, et al. (2011) Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem Biol Drug Des 77: 39-47.
79. Billamboz M, Bailly F, Barreca ML, De LL, Mouscadet JF, et al. (2008) Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J Med Chem 51: 7717-7730.
80. Zu Putlitz J, Lanford RE, Carlson RI, Notvall L, de la Monte SM, et al. (1999) Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J Virol 73: 4188-4196.
81. Kurbanov F, Tanaka Y, Mizokami M, (2010) Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 40: 14-30.
82. Cao F, Donlin MJ, Turner K, Cheng X, Tavis JE, (2011) Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon alpha plus ribavirin therapy. J Viral Hepat 18: 349-357.
83. Lima WF, Rose JB, Nichols JG, Wu H, Migawa MT, et al. (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol 71: 83-91.
84. Lima WF, Wu H, Crooke ST, (2001) Human RNases H. Methods Enzymol 341: 430-440.
85. Liaw YF, (2011) Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 31 Suppl 1: 117-121.
86. Tavis JE, Ganem D, (1993) Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription. Proc Natl Acad Sci U S A 90: 4107-4111.
87. Hu J, Anselmo D, (2000) In vitro reconstitution of a functional duck hepatitis b virus reverse transcriptase: posttranslational activation by HSP90. J Virol 74: 11447-11455.
88. Beck J, Nassal M, (2003) Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein. J Biol Chem 278: 36128-36138.
89. Lin L, Wan F, Hu J, (2008) Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions. J Virol 82: 5703-5714.
90. Arnold JJ, Ghosh SK, Cameron CE, (1999) Poliovirus RNA-dependent RNA polymerase (3D(pol)). Divalent cation modulation of primer, template, and nucleotide selection. JBiolChem 274: 37060-37069.
91. Pelletier H, Sawaya MR, Wolfle W, Wilson SH, Kraut J, (1996) A structural basis for metal ion mutagenicity and nucleotide selectivity in human DNA polymerase beta. Biochemistry 35: 12762-12777.
92. Sturmer M, Doerr HW, Gurtler L, (2009) Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol 198: 147-155.
93. Agrawal A, DeSoto J, Fullagar JL, Maddali K, Rostami S, et al. (2012) Probing chelation motifs in HIV integrase inhibitors. Proc Natl Acad Sci U S A 109: 2251-2256.
94. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, et al. (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126: 280-289.
95. Vanlandschoot P, Van HF, Roobrouck A, Farhoudi A, Leroux-Roels G, (2002) Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. J Gen Virol 83: 1281-1289.
96. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL, (2011) Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 6: e15324.
97. Wu J, Meng Z, Jiang M, Pei R, Trippler M, et al. (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49: 1132-1140.
98. Xu Y, Hu Y, Shi B, Zhang X, Wang J, et al. (2009) HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 46: 2640-2646.
99. Cheng J, Imanishi H, Morisaki H, Liu W, Nakamura H, et al. (2005) Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1. J Hepatol 43: 465-471.
100. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, et al. (2005) Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79: 3016-3027.
101. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, et al. (2004) A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 101: 14913-14918.
102. Wang H, Ryu WS, (2010) Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6: e1000986.
103. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, et al. (1991) Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A 88: 2888-2892.
104. Wu M, Xu Y, Lin S, Zhang X, Xiang L, et al. (2007) Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 88: 3260-3269.
105. Tavis JE, Massey B, Gong Y, (1998) The Duck Hepatitis B Virus Polymerase Is Activated by Its RNA Packaging Signal, Epsilon. J Virol 72: 5789-5796.
106. Edward JT, Gauthier M, Chubb FL, Ponka P, (1988) Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data 33: 538-540.